Jane Eyre readily admits that while working as a hairdresser in Melbourne more than 20 years ago “I probably drank more gin and tonic,” but a flair for coaxing top-notch wines from storied Burgundy vines has propelled her into the French wine firmament.
“There’s nothing like making your own wine,” Eyre said while inspecting a glass of Savigny-les-Beaune premier cru aux Vergelesses, one of a half-dozen of her recent reds.
French peers believe there is nothing quite like her wines: This month Eyre became the first Australian, and the first woman, to win the Negociant of the Year award by the Revue du Vin de France (RVF), an insider’s guide to France’s finest bottles.
Warning: Excessive consumption of alcohol can damage your health
The prestigious title recognizes the talent of a particular brand of winemaker — independent players who do not own vineyards, but buy grapes from others to make their own.
While the term translates as “merchant,” it has a distinctive meaning in Burgundy, where it is effectively a license to buy grapes or bulk wine for production and resale, although often they end up as underwhelming, low-price tipples.
For Eyre, who grew up in Gippsland, Victoria, on Australia’s southeast coast — where she now also makes a wine she imports to France — it was the easiest way to chase a dream sparked by a conversation she had while cutting a client’s hair.
Soon afterward, she quit her job and headed to France in 1998, where she helped with the harvest at the family-owned Domaine Chevrot, eventually working at other houses in Burgundy, as well as in the Mosel region in Germany, while also obtaining a winemaking degree back home.
A few years later, she landed at a vineyard owned by New Orleans native Chris Newman, becoming his assistant while also making her own wines on the side.
“I started with nothing. A friend lent me 5,000 euros [US$6,040 at the current exchange rate] and my boss gave me my first new barrel,” she said.
Eyre now works with a handful of growers to know exactly when their grapes are going to peak, and shows up to handle her harvests herself, “so I know exactly what I’m getting,” she said.
With stocks from celebrated vineyards such as Volney, Corton or Gevrey-Chambertin, she then oversees the fermentation and aging at a shared “wine studio” at the Chateau de Bligny outside Beaune.
In the cellar, she also dips every bottle top in wax to cover the cork, and applies her subdued white labels by hand.
Critics and top restaurants such as La Tour d’Argent or Pierre Gagnaire have lauded a deft touch that let the grapes, in particular her favorite pinot noirs, reach their full potential.
Her wines also line the shelves of top Paris wine boutiques such as Legrand or the Livre de Cave, a specialist in rare finds.
The Revue du Vin deemed her bottles “superb” and called Eyre “one to watch closely” in the coming years.
“I was overwhelmed. RVF has been a reference for great wines, it’s like the Michelin for wines,” Eyre said, adding that “40 years ago, women were not allowed in the cellar at a certain period of the month.”
Looking ahead, Eyre said that she would love to eventually have her own winery, although demand for coveted Burgundy fields has made the region a playground for the rich.
“To take that next step to buy a vineyard I’d need an investor,” she said. “If you buy half a hectare of a Grand Cru, you’d be up for a few million.”
However, with her 20,000 bottles a year, Eyre is already “shifting negociant wines to tailor-made bottles at the high end of the market, even for the simplest vintages.”
“It shows that it’s not only the French who can make wines,” Eyre said. “It opens the doors.”
JPMorgan Chase & Co chief executive officer Jamie Dimon on Tuesday quipped that his company is likely to outlast the Chinese Communist Party (CCP), while reiterating the bank’s commitment to the country in wide-ranging comments that also touched on Taiwan, free speech and former US president Donald Trump. “We hope to be there [in China] for a long time,” Dimon told a panel discussion at the Boston College Chief Executives Club. Relaying a “joke” he made during a recent visit to Hong Kong, he said “The communist party is celebrating its 100th year. So is JPMorgan. And I’ll make you a
The Kaohsiung City Government yesterday said it would impose a property hoarding tax as it is seeking to contain speculation in the real-estate market, calling recent price increases “abnormal.” The announcement came in support of the Ministry of Finance’s call for local governments to levy a high tax rate on people with more than one property. Ministry officials on Tuesday discussed strategies to rein in speculation with the nation’s six special municipalities, as well as the Hsinchu city and county governments. About 84,000 out of 1.06 million housing units in Kaohsiung are not residential property, the city government said in a
BOOST EXPECTED: Higher market prices would offset effects of the industry’s transition to more climate-friendly production methods, a company official said China Steel Corp (CSC, 中鋼) expects steel demand to increase on the back of governments around the world subsidizing infrastructure construction amid a stabilizing COVID-19 pandemic, CSC chairman Wong Chao-tung (翁朝棟) told an investors’ meeting yesterday. “After getting through the hard times, I foresee at least one year, very possibly two years, of strong steel market,” Wong said. Calling a dip in steel prices a “short respite for the market,” Wong said that it would likely bounce back early next year on the back of mild winter temperatures around the world allowing construction activity. Despite COVID-19 spikes in some regions and increased
PharmaEssentia Corp (藥華醫藥) shares have jumped 80.56 percent since the company obtained a US polycythemia vera (PV) drug license for its new interferon drug Besremi (ropeginterferon alfa-2b-njft) on Nov. 12. Shares on Friday closed at NT$195 in Taipei trading, up from the stock’s closing price of NT$108 on Nov. 12. PV is a rare, chronic and life-threatening blood cancer linked to a stem cell mutation in the bone marrow that results in an overproduction of blood cells and places sufferers at risk of having a blood clot, stroke or heart attack. PharmaEssentia is preparing to make Besremi available in the US in the